18F-PSMA-1007 PET/CT 用于终末期肾病患者肾细胞癌的初始分期。
18F-PSMA-1007 PET/CT for Initial Staging of Renal Cell Carcinoma in an End-Stage Renal Disease Patient.
机构信息
From the Sheikh Jaber Al Ahmad Al Sabah for Nuclear Medicine and Molecular Imaging Center, Kuwait City, Kuwait.
Department of Nuclear Medicine, St Gregorios International Cancer Care Centre, Pathanamthitta, Kerala, India.
出版信息
Clin Nucl Med. 2021 Jan;46(1):e65-e67. doi: 10.1097/RLU.0000000000003354.
A 46-year-old man with end-stage renal disease and renal cell carcinoma underwent F-FDG PET/CT for initial staging followed by F-PSMA-1007 PET/CT. Unlike F-FDG, which undergoes renal clearance, F-PSMA-1007 undergoes hepatobiliary clearance and thus generates superior quality images. F-PSMA-1007 PET/CT showed intense tracer-avid left renal mass lesion (FDG nonavid); lytic bone lesions (FDG avid) and single liver lesion (FDG nonavid). This case highlights the superiority of F-PSMA-1007 over F-FDG PET/CT in identifying primary lesion as well as metastatic sites in case of renal cell carcinoma even in the presence of end-stage renal disease.
一位 46 岁的终末期肾病和肾细胞癌患者进行了 F-FDG PET/CT 初始分期，随后进行了 F-PSMA-1007 PET/CT。与经历肾脏清除的 F-FDG 不同，F-PSMA-1007 经历肝胆清除，因此生成的图像质量更高。F-PSMA-1007 PET/CT 显示左肾肿块病变（FDG 无摄取）、溶骨性骨病变（FDG 摄取）和单个肝病变（FDG 无摄取）摄取强烈示踪剂。即使在终末期肾病的情况下，该病例也突出了 F-PSMA-1007 在识别肾细胞癌的原发性病变和转移部位方面优于 F-FDG PET/CT。
Zotero 插件